Access to capital, government red tape among top barriers cited by biotech firms, survey finds
By Jolson LimSep. 26, 2018
Though the industry believes the federal government's flagship innovation program, SR&ED, is important and useful, all say it could use some tweaks.
A scientist working at Spartan, a biotech firm located in Ottawa, is pictured in 2017. The biotech industry in Canada is expanding, although investment issues remain, according to a recent survey. The Hill Times photograph by Sam Garcia
Access to capital remains the biggest challenge for Canada’s biotechnology sector, even as most of its companies have tapped into federal programs offered to startup companies, according to a new report released on Sept. 24.
People. Policy. Politics. This is an exclusive subscriber-only story.
Gerald Butts has removed himself from the daily political grind of strategizing how to keep the Liberals in power. But observers say it's unlikely he will be consigned to watch the campaign unfold from the sidelines.
SNC-Lavalin risks a takeover if it's convicted. But aside from likely outrage in Quebec, Ottawa can find other builders for its infrastructure plans if the company is banned from bidding on federal contracts, experts say
The Quebec company had extensive access to government ministers and top staffers, and was the only organization registered to lobby for allowing deferred prosecution agreements for white collar crimes.